Obseva Stock Price, News & Analysis (NASDAQ:OBSV)

$14.13 +1.65 (+13.22 %)
(As of 02/18/2018 04:00 PM ET)
Previous Close$14.13
Today's Range$12.31 - $14.59
52-Week Range$5.00 - $14.69
Volume70,477 shs
Average Volume45,011 shs
Market Capitalization$524.66 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Obseva (NASDAQ:OBSV)

Obseva logoObseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109 is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and blocks the endogenous GnRH from activating its pituitary receptors, which reduces estrogen production by the ovaries and leads to amenorrhea. OBE001 (nolasiban) is an oral, new generation oxytocin antagonist with the potential to inhibit uterine contractions at the time of embryo transfer, thereby enhancing embryo implantation during assisted reproductive technologies (ART). BE022 is an orally active small molecule dinoprost (PGF2a) receptor antagonist.

Receive OBSV News and Ratings via Email

Sign-up to receive the latest news and ratings for OBSV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:OBSV
CUSIPN/A
Phone41-0-22-552-3840

Debt

Debt-to-Equity RatioN/A
Current Ratio8.37%
Quick Ratio8.37%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.22 per share
Price / Book11.58

Profitability

Trailing EPSN/A
Net Income$-30,200,000.00
Net MarginsN/A
Return on Equity-74.99%
Return on Assets-66.38%

Miscellaneous

Employees27
Outstanding Shares37,130,000

Obseva (NASDAQ:OBSV) Frequently Asked Questions

What is Obseva's stock symbol?

Obseva trades on the NASDAQ under the ticker symbol "OBSV."

How were Obseva's earnings last quarter?

Obseva SA (NASDAQ:OBSV) released its quarterly earnings data on Tuesday, November, 14th. The company reported ($0.59) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.58) by $0.01. The company's revenue for the quarter was up NaN% on a year-over-year basis. View Obseva's Earnings History.

When will Obseva make its next earnings announcement?

Obseva is scheduled to release their next quarterly earnings announcement on Tuesday, February, 20th 2018. View Earnings Estimates for Obseva.

Where is Obseva's stock going? Where will Obseva's stock price be in 2018?

6 brokerages have issued 1 year price objectives for Obseva's shares. Their predictions range from $16.00 to $25.00. On average, they anticipate Obseva's share price to reach $20.33 in the next twelve months. View Analyst Ratings for Obseva.

What are Wall Street analysts saying about Obseva stock?

Here are some recent quotes from research analysts about Obseva stock:

  • 1. According to Zacks Investment Research, "ObsEva SA is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics for woman's reproductive health and pregnancy. ObsEva SA is headquartered in Geneva, Switzerland. " (12/19/2017)
  • 2. Jefferies Group LLC analysts commented, "We view OBSV shares as attractive based on lead asset OBE2109 in two prevalent gynecologic conditions. We see the dev'l strategy and superior PK profile of OBE2109 supportive of best-in-class pot'l. The stock is undervalued in our opinion as it trades at a 2x discount to its closest competitor, despite an experienced mgmt team w/ a proven track record in women's health. We initiate with a Buy rating and a $21 PT." (2/21/2017)

Who are some of Obseva's key competitors?

Who are Obseva's key executives?

Obseva's management team includes the folowing people:

  • Frank Verwiel M.D., , Independent Chairman of the Board (Age 54)
  • Ernest Loumaye M.D., Ph.D., Chief Executive Officer, Director (Age 64)
  • Timothy M. Adams, Chief Financial Officer (Age 58)
  • Jean-Pierre Gotteland Ph.D., Chief Scientific Officer (Age 52)
  • Fabien Lefebvre de Ladonchamps, Vice President - Finance (Age 38)
  • Ben T.G. Tan, Vice President - Commercial & Business Development (Age 58)
  • Elke Bestel, Chief Medical Officer and Head of Pharmacovigilance (Age 50)
  • Nanna Luneborg Ph.D., Director (Age 41)
  • Annette V. Clancy, Independent Director (Age 63)
  • Barbara G. Duncan, Independent Director (Age 52)

When did Obseva IPO?

(OBSV) raised $98 million in an IPO on Thursday, January 26th 2017. The company issued 6,500,000 shares at a price of $14.00-$16.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO.

Who owns Obseva stock?

Obseva's stock is owned by a number of of retail and institutional investors. Top institutional investors include Sofinnova Management VIII L.L.C. (12.79%), VHCP Management II LLC (5.36%), Omega Fund Management LLC (2.69%), First Manhattan Co. (2.69%) and Sphera Funds Management LTD. (1.48%). View Institutional Ownership Trends for Obseva.

Who bought Obseva stock? Who is buying Obseva stock?

Obseva's stock was purchased by a variety of institutional investors in the last quarter, including Sofinnova Management VIII L.L.C., Omega Fund Management LLC, First Manhattan Co., VHCP Management II LLC and Sphera Funds Management LTD.. View Insider Buying and Selling for Obseva.

How do I buy Obseva stock?

Shares of Obseva can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Obseva's stock price today?

One share of Obseva stock can currently be purchased for approximately $14.13.

How big of a company is Obseva?

Obseva has a market capitalization of $524.66 million. Obseva employs 27 workers across the globe.

How can I contact Obseva?

Obseva's mailing address is Chemin des Aulx 12 Plan-les-Ouates, Geneva V8, 1228. The company can be reached via phone at 41-0-22-552-3840 or via email at [email protected]


MarketBeat Community Rating for Obseva (OBSV)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  84 (Vote Outperform)
Underperform Votes:  84 (Vote Underperform)
Total Votes:  168
MarketBeat's community ratings are surveys of what our community members think about Obseva and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Obseva (NASDAQ:OBSV) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $20.33$20.33$20.40$23.25
Price Target Upside: 84.85% upside106.85% upside88.34% upside202.54% upside

Obseva (NASDAQ:OBSV) Consensus Price Target History

Price Target History for Obseva (NASDAQ:OBSV)

Obseva (NASDAQ:OBSV) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/5/2018HC WainwrightReiterated RatingBuy$25.00LowView Rating Details
12/4/2017BMO Capital MarketsInitiated CoverageOutperform$20.00LowView Rating Details
11/2/2017Royal Bank of CanadaReiterated RatingBuy$22.00N/AView Rating Details
10/9/2017Credit Suisse GroupInitiated CoverageOutperform$27.00 -> $16.00N/AView Rating Details
8/16/2017Leerink SwannReiterated RatingOutperform -> Outperform$18.00HighView Rating Details
2/21/2017Jefferies GroupInitiated CoverageBuy -> Buy$21.00N/AView Rating Details
(Data available from 2/18/2016 forward)

Earnings

Obseva (NASDAQ:OBSV) Earnings History and Estimates Chart

Earnings by Quarter for Obseva (NASDAQ:OBSV)

Obseva (NASDAQ OBSV) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/20/2018        
11/14/2017n/a($0.58)($0.59)ViewN/AView Earnings Details
8/15/20176/30/2017($0.48)($0.61)$0.01 millionViewN/AView Earnings Details
5/18/20173/31/2017($0.41)($0.58)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Obseva (NASDAQ:OBSV) Earnings Estimates

2018 EPS Consensus Estimate: ($2.44)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.54)($0.54)($0.54)
Q2 20181($0.58)($0.58)($0.58)
Q3 20181($0.63)($0.63)($0.63)
Q4 20181($0.69)($0.69)($0.69)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Obseva (NASDAQ:OBSV)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Obseva (NASDAQ OBSV)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Obseva (NASDAQ OBSV) News Headlines

Source:
DateHeadline
ObsEva SA to present at the LEERINK Partners 7th Annual Global Healthcare Conference February 14th 2018ObsEva SA to present at the LEERINK Partners 7th Annual Global Healthcare Conference February 14th 2018
finance.yahoo.com - February 15 at 8:54 AM
Obseva SA (OBSV) Receives Average Rating of "Buy" from BrokeragesObseva SA (OBSV) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - February 11 at 1:28 AM
Obseva (OBSV) Stock Rating Reaffirmed by HC WainwrightObseva (OBSV) Stock Rating Reaffirmed by HC Wainwright
www.americanbankingnews.com - February 5 at 7:40 PM
Dr. Ernest Loumaye, CEO of ObsEva SA returns to work following a personal leave for medical reasonsDr. Ernest Loumaye, CEO of ObsEva SA returns to work following a personal leave for medical reasons
finance.yahoo.com - February 1 at 9:04 AM
ObsEva SA (OBSV) Given Consensus Rating of "Buy" by AnalystsObsEva SA (OBSV) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - January 17 at 1:48 AM
Head-To-Head Review: ObsEva (OBSV) versus Its PeersHead-To-Head Review: ObsEva (OBSV) versus Its Peers
www.americanbankingnews.com - January 12 at 3:16 AM
ObsEva (OBSV) versus The Competition Head to Head ReviewObsEva (OBSV) versus The Competition Head to Head Review
www.americanbankingnews.com - January 7 at 11:26 PM
Comparing Athersys (ATHX) & ObsEva (OBSV)Comparing Athersys (ATHX) & ObsEva (OBSV)
www.americanbankingnews.com - December 27 at 1:16 PM
Zacks Investment Research Downgrades ObsEva (OBSV) to HoldZacks Investment Research Downgrades ObsEva (OBSV) to Hold
www.americanbankingnews.com - December 24 at 1:52 PM
ObsEva SA (OBSV) Given Consensus Rating of "Buy" by BrokeragesObsEva SA (OBSV) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - December 23 at 1:52 AM
ObsEva (OBSV) Receives "Buy" Rating from HC WainwrightObsEva (OBSV) Receives "Buy" Rating from HC Wainwright
www.americanbankingnews.com - December 14 at 9:22 AM
ObsEva SA to Participate in BMO Healthcare Conference December 14th 2017ObsEva SA to Participate in BMO Healthcare Conference December 14th 2017
finance.yahoo.com - December 7 at 9:04 AM
ObsEva SA (OBSV) Commences PROLONG, the Phase 2A Clinical Trial of OBE022 in Preterm LaborObsEva SA (OBSV) Commences PROLONG, the Phase 2A Clinical Trial of OBE022 in Preterm Labor
www.streetinsider.com - December 6 at 5:47 PM
ObsEva Initiates PROLONG, the Phase 2a Clinical Trial of OBE022 in Preterm LaborObsEva Initiates PROLONG, the Phase 2a Clinical Trial of OBE022 in Preterm Labor
finance.yahoo.com - December 5 at 9:40 AM
BMO Capital Markets Initiates Coverage on ObsEva (OBSV)BMO Capital Markets Initiates Coverage on ObsEva (OBSV)
www.americanbankingnews.com - December 4 at 8:22 PM
ObsEva (OBSV) Given a $25.00 Price Target by HC Wainwright AnalystsObsEva (OBSV) Given a $25.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - November 29 at 1:00 PM
ObsEva SA (OBSV) Given Consensus Recommendation of "Buy" by BrokeragesObsEva SA (OBSV) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - November 28 at 1:36 AM
FY2017 EPS Estimates for ObsEva SA Increased by Leerink Swann (OBSV)FY2017 EPS Estimates for ObsEva SA Increased by Leerink Swann (OBSV)
www.americanbankingnews.com - November 17 at 8:30 PM
ObsEva Reports Third Quarter 2017 Financial Results and Provides Business UpdateObsEva Reports Third Quarter 2017 Financial Results and Provides Business Update
finance.yahoo.com - November 15 at 7:00 AM
Edited Transcript of OBSV.O earnings conference call or presentation 14-Nov-17 1:00pm GMTEdited Transcript of OBSV.O earnings conference call or presentation 14-Nov-17 1:00pm GMT
finance.yahoo.com - November 15 at 7:00 AM
ObsEva SA (OBSV) Posts Quarterly  Earnings Results, Misses Expectations By $0.01 EPSObsEva SA (OBSV) Posts Quarterly Earnings Results, Misses Expectations By $0.01 EPS
www.americanbankingnews.com - November 14 at 9:10 AM
ObsEva SAs (OBSV) "Buy" Rating Reaffirmed at HC WainwrightObsEva SA's (OBSV) "Buy" Rating Reaffirmed at HC Wainwright
www.americanbankingnews.com - November 8 at 10:26 PM
ObsEva SA (OBSV) Reports Completion of Patient Recruitment in the EDELWEISS Phase 2b Clinical Trial of OBE2109ObsEva SA (OBSV) Reports Completion of Patient Recruitment in the EDELWEISS Phase 2b Clinical Trial of OBE2109
www.streetinsider.com - November 7 at 9:43 PM
ObsEva SA (OBSV) to Release Earnings on TuesdayObsEva SA (OBSV) to Release Earnings on Tuesday
www.americanbankingnews.com - November 7 at 8:32 AM
ObsEva SA Announces the Completion of Patient Recruitment in the EDELWEISS Phase 2b Clinical Trial of OBE2109 for the Treatment of EndometriosisObsEva SA Announces the Completion of Patient Recruitment in the EDELWEISS Phase 2b Clinical Trial of OBE2109 for the Treatment of Endometriosis
finance.yahoo.com - November 7 at 8:04 AM
ObsEva SA (OBSV) Given "Buy" Rating at Royal Bank Of CanadaObsEva SA (OBSV) Given "Buy" Rating at Royal Bank Of Canada
www.americanbankingnews.com - November 2 at 3:20 PM
ObsEva SA to Hold Third Quarter 2017 Financial Results and Business Update Call on November 14, 2017 and Present at Credit Suisse and Jefferies Investor Conferences in NovemberObsEva SA to Hold Third Quarter 2017 Financial Results and Business Update Call on November 14, 2017 and Present at Credit Suisse and Jefferies Investor Conferences in November
finance.yahoo.com - October 31 at 7:21 AM
HC Wainwright Reiterates "Buy" Rating for ObsEva SA (OBSV)HC Wainwright Reiterates "Buy" Rating for ObsEva SA (OBSV)
www.americanbankingnews.com - October 30 at 8:22 AM
ObsEva SA (OBSV) Earns "Buy" Rating from HC WainwrightObsEva SA (OBSV) Earns "Buy" Rating from HC Wainwright
www.americanbankingnews.com - October 15 at 10:56 PM
ObsEva SA (OBSV) Announces $60M Private PlacementObsEva SA (OBSV) Announces $60M Private Placement
www.streetinsider.com - October 11 at 5:54 AM
ObsEva SA Announces $60.0 Million Private Placement with Existing and New InvestorsObsEva SA Announces $60.0 Million Private Placement with Existing and New Investors
finance.yahoo.com - October 11 at 5:54 AM
ObsEva SA (OBSV) Coverage Initiated at Credit Suisse GroupObsEva SA (OBSV) Coverage Initiated at Credit Suisse Group
www.americanbankingnews.com - October 9 at 10:02 AM
ObsEva SA (OBSV) Given Average Recommendation of "Buy" by BrokeragesObsEva SA (OBSV) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - October 9 at 2:42 AM
Royal Bank Of Canada Begins Coverage on ObsEva SA (OBSV)Royal Bank Of Canada Begins Coverage on ObsEva SA (OBSV)
www.americanbankingnews.com - September 14 at 10:35 PM
ObsEva SA Announces Presentation Related to its PGF2alpha Receptor Antagonist at ACCP 2017 Annual MeetingObsEva SA Announces Presentation Related to its PGF2alpha Receptor Antagonist at ACCP 2017 Annual Meeting
finance.yahoo.com - September 12 at 7:42 AM
ObsEva SA (OBSV) Stock Rating Reaffirmed by HC WainwrightObsEva SA (OBSV) Stock Rating Reaffirmed by HC Wainwright
www.americanbankingnews.com - September 8 at 6:44 PM
ObsEva SA Announces the Completion of Patient Recruitment in the IMPLANT2 Phase 3 Clinical Trial inObsEva SA Announces the Completion of Patient Recruitment in the IMPLANT2 Phase 3 Clinical Trial in
www.nasdaq.com - September 7 at 7:06 AM
ObsEva SA Announces the Completion of Patient Recruitment in the IMPLANT2 Phase 3 Clinical Trial in Assisted Reproductive Technology Ahead of ScheduleObsEva SA Announces the Completion of Patient Recruitment in the IMPLANT2 Phase 3 Clinical Trial in Assisted Reproductive Technology Ahead of Schedule
finance.yahoo.com - September 6 at 7:07 AM
ObsEva SA: ObsEva SA to Attend Baird Global Healthcare Conference and Rodman & Renshaw Annual Global Investment Conference in NYCObsEva SA: ObsEva SA to Attend Baird Global Healthcare Conference and Rodman & Renshaw Annual Global Investment Conference in NYC
www.finanznachrichten.de - August 30 at 7:31 AM
ObsEva SA to Attend Baird Global Healthcare Conference and Rodman & Renshaw Annual Global Investment Conference in NYCObsEva SA to Attend Baird Global Healthcare Conference and Rodman & Renshaw Annual Global Investment Conference in NYC
finance.yahoo.com - August 30 at 7:31 AM
Edited Transcript of OBSV.O earnings conference call or presentation 15-Aug-17 9:00pm GMTEdited Transcript of OBSV.O earnings conference call or presentation 15-Aug-17 9:00pm GMT
finance.yahoo.com - August 19 at 6:10 AM
ObsEva SA Forecasted to Post Q3 2017 Earnings of ($0.65) Per Share (OBSV)ObsEva SA Forecasted to Post Q3 2017 Earnings of ($0.65) Per Share (OBSV)
www.americanbankingnews.com - August 18 at 6:42 AM
ObsEva SA (OBSV) Forecasted to Post Q3 2017 Earnings of ($0.67) Per ShareObsEva SA (OBSV) Forecasted to Post Q3 2017 Earnings of ($0.67) Per Share
www.americanbankingnews.com - August 18 at 6:42 AM
ObsEva SAs (OBSV) "Outperform" Rating Reaffirmed at Leerink SwannObsEva SA's (OBSV) "Outperform" Rating Reaffirmed at Leerink Swann
www.americanbankingnews.com - August 16 at 1:06 PM
ObsEva SA (OBSV) PT Set at $27.00 by HC WainwrightObsEva SA (OBSV) PT Set at $27.00 by HC Wainwright
www.americanbankingnews.com - August 16 at 8:02 AM
ALXNs Strengthening Patents, FOLDs Fabry Drug Approved In OZ, VBIV SurgesALXN's Strengthening Patents, FOLD's Fabry Drug Approved In OZ, VBIV Surges
www.rttnews.com - August 16 at 2:42 AM
ObsEva SA (OBSV) Releases Quarterly  Earnings Results, Misses Estimates By $0.13 EPSObsEva SA (OBSV) Releases Quarterly Earnings Results, Misses Estimates By $0.13 EPS
www.americanbankingnews.com - August 15 at 7:26 PM
ObsEva Reports Second Quarter 2017 Financial Results and Provides Business UpdateObsEva Reports Second Quarter 2017 Financial Results and Provides Business Update
finance.yahoo.com - August 15 at 4:39 PM
ObsEva SA (OBSV) Set to Announce Earnings on TuesdayObsEva SA (OBSV) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - August 8 at 10:44 AM
ObsEva SA to Hold Second Quarter 2017 Financial Results/Business Update Call on August 15, 2017 and Present at Wedbush PacGrow Healthcare Conference in NYC on August 16, 2017ObsEva SA to Hold Second Quarter 2017 Financial Results/Business Update Call on August 15, 2017 and Present at Wedbush PacGrow Healthcare Conference in NYC on August 16, 2017
feeds.benzinga.com - August 7 at 7:16 AM

SEC Filings

Obseva (NASDAQ:OBSV) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Obseva (NASDAQ:OBSV) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Obseva (NASDAQ OBSV) Stock Chart for Sunday, February, 18, 2018

Loading chart…

This page was last updated on 2/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.